Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 9/20 | 0.44 |
| ▸ | TBK1 | Q9UHD2 | 8/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | GNRHR | P30968 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13985729 | 0.96 | TBK1 (0.44) | AURKATBK1GNRHR | |
| SCHEMBL211958 | 0.89 | AURKA (0.52) | AURKATBK1KCNH2GNRHRALK | |
| SCHEMBL13985647 | 0.88 | AURKA (0.51) | AURKATBK1ALK | |
| SCHEMBL4757746 | 0.87 | TBK1 (0.51) | AURKATBK1 | |
| SCHEMBL13985463 | 0.87 | AURKA (0.42) | AURKAKCNH2GNRHR | |
| SCHEMBL13985741 | 0.86 | AURKA (0.43) | AURKATBK1ALK | |
| SCHEMBL13985465 | 0.84 | AURKA (0.51) | AURKADRD2DRD4DRD3FLT3 | |
| SCHEMBL210953 | 0.84 | AURKA (0.54) | AURKATBK1KCNH2GNRHR | |
| SCHEMBL4757466 | 0.84 | AURKA (0.64) | AURKAFLT3KCNH2 | |
| SCHEMBL211868 | 0.82 | AURKA (0.48) | AURKATBK1FLT3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009001021-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS ENZYME INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE AND AUTOIMMUNE DISEASES | CHROMA THERAPEUTICS LTD. (GB) | 2008-12-31 | — | — | WO | disclosed |